Free Trial

Immunic, Inc. (NASDAQ:IMUX) Short Interest Up 55.7% in May

Immunic logo with Medical background

Immunic, Inc. (NASDAQ:IMUX - Get Free Report) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 4,250,000 shares, a growth of 55.7% from the May 15th total of 2,730,000 shares. Based on an average daily trading volume, of 1,350,000 shares, the days-to-cover ratio is currently 3.1 days. Approximately 4.9% of the company's stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on IMUX. HC Wainwright reissued a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday, May 1st. William Blair reissued an "outperform" rating on shares of Immunic in a research note on Friday, May 16th. Wall Street Zen cut shares of Immunic from a "hold" rating to a "sell" rating in a research note on Thursday, March 20th. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Immunic in a research note on Thursday, June 5th. Finally, B. Riley reissued a "buy" rating and issued a $5.00 target price (down from $6.00) on shares of Immunic in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average target price of $11.60.

View Our Latest Stock Analysis on Immunic

Immunic Price Performance

Immunic stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.75. 1,188,614 shares of the company's stock traded hands, compared to its average volume of 893,859. The firm has a 50 day simple moving average of $0.94 and a two-hundred day simple moving average of $1.03. Immunic has a fifty-two week low of $0.56 and a fifty-two week high of $2.11. The stock has a market cap of $71.87 million, a price-to-earnings ratio of -0.61 and a beta of 1.48.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.25) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.25). On average, research analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immunic

Hedge funds and other institutional investors have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in shares of Immunic during the fourth quarter worth $37,000. Barclays PLC acquired a new stake in shares of Immunic during the fourth quarter worth $84,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Immunic by 90.0% during the fourth quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 204,579 shares of the company's stock worth $205,000 after buying an additional 96,894 shares in the last quarter. Bridgeway Capital Management LLC lifted its holdings in shares of Immunic by 11.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock worth $215,000 after buying an additional 22,200 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in shares of Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company's stock worth $226,000 after buying an additional 152,726 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

About Immunic

(Get Free Report)

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.

Featured Stories

Should You Invest $1,000 in Immunic Right Now?

Before you consider Immunic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunic wasn't on the list.

While Immunic currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines